Annonce • Apr 07
Cannara Biotech Inc. to Report Q2, 2026 Results on Apr 14, 2026 Cannara Biotech Inc. announced that they will report Q2, 2026 results at 7:00 AM, US Eastern Standard Time on Apr 14, 2026 Annonce • Feb 05
Cannara Biotech Inc. announced that it has received CAD 6.3 million in funding from Phoenician Capital LLC and another investor Cannara Biotech Inc. announced a non-brokered private placement of 3,000,000 common shares of the Company at a price of CAD 2.10 per Common Share for gross proceeds of CAD 6,300,000 on February 4, 2026. The transaction involves participation from new investor Phoenician Capital LLC. The issue price of the Common Shares represents an approximate 16% premium to the Company’s closing price on February 3, 2026, the last trading day prior to the announcement of the Private Placement. The Common Shares issued in connection with the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the TSXV. No finder’s fees or commissions were paid in connection with the Private Placement. The transaction is subject to final acceptance of the TSX Venture Exchange. The Company further announces that Zohar Krivorot has entered into an agreement to sell, on an exempt basis, 333,333 Common Shares of the Company to Phoenician at a price of CAD 2.10 per Common Share. The Company is not a party to the Secondary Share Sale and will not receive any proceeds from the transaction, which was undertaken solely to offset personal tax losses arising due to the recent vesting of certain restricted share units in the Company. The Common Shares sold to Phoenician under the Secondary Share sale are also subject to restrictions on transfer for a period of four months and one day. Prior to completion of the Secondary Share Sale, the individual investor beneficially owns or exercises control or direction over, directly or indirectly, 25,852,540 Common Shares of the Company, representing approximately 26.99% of the issued and outstanding Common Shares. Upon completion of the Secondary Share Sale, individual investor is expected to beneficially own or exercise control or direction over, directly or Cannara Biotech Inc 2 indirectly, 25,519,207 Common Shares of the Company, representing approximately 25.83% of the issued and outstanding Common Shares, after giving effect to the Private Placement. Annonce • Jan 14
Cannara Biotech Inc. to Report Q1, 2026 Results on Jan 26, 2026 Cannara Biotech Inc. announced that they will report Q1, 2026 results at 7:00 AM, US Eastern Standard Time on Jan 26, 2026 Annonce • Nov 26
Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026 Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026. Annonce • Nov 18
Cannara Biotech Inc. Announces the Passing of Jack M. Kay Member of the Board of Director Cannara Biotech Inc. announced the passing of Jack M. Kay, a long-serving and highly respected member of the Board of Directors. Mr. Kay, who joined the Board in 2019, contributed more than five decades of leadership experience in pharmaceutical and sales executive management to the Corporation. Mr. Kay spent 35 years at Apotex Inc., where he held several senior executive positions, including Chief Executive Officer, Chief Operating Officer, President, and Vice Chairman. He also served in key leadership roles across the pharmaceutical and biotechnology sectors, including Chairman of Helix Biopharma Corp. and Cangene Corp., and Director of Barr Pharmaceuticals Inc. In addition to his industry contributions, Mr. Kay was a dedicated community leader, notably serving as Chairman of the Humber River Regional Hospital (Toronto) and as an executive member of several healthcare and industry organizations. Annonce • Nov 17
Cannara Biotech Inc. to Report Q4, 2025 Results on Nov 24, 2025 Cannara Biotech Inc. announced that they will report Q4, 2025 results at 7:00 AM, US Eastern Standard Time on Nov 24, 2025 Annonce • Jul 21
Cannara Biotech Inc. to Report Q3, 2025 Results on Jul 28, 2025 Cannara Biotech Inc. announced that they will report Q3, 2025 results at 7:00 AM, US Eastern Standard Time on Jul 28, 2025 Annonce • Apr 16
Cannara Biotech Inc. to Report Q2, 2025 Results on Apr 28, 2025 Cannara Biotech Inc. announced that they will report Q2, 2025 results at 7:00 AM, US Eastern Standard Time on Apr 28, 2025 Annonce • Mar 24
Cannara Biotech Inc. Announces Appointment of Justin Cohen to Board of Directors Cannara Biotech Inc. announced the appointment of Mr. Justin Cohen to its board of directors as an independent director. Mr. Cohen will also serve as a member of the Audit Committee. Mr. Cohen is a seasoned executive with a track record of driving transformational growth and providing valuable leadership in brand development, sales and marketing. As Chief Marketing and Chief Commercial Officer at Psycho Bunny, he spearheaded the brand’s evolution from a niche player to a global powerhouse. Under his leadership, revenues increased tenfold over three years, driven by strategic retail expansion, digital acceleration, and brand reinvention. Prior to Psycho Bunny, Mr. Cohen led direct-to-consumer and e-commerce strategy at Keurig Dr Pepper, expanding its digital footprint and scaling revenue across online and omnichannel platforms. He has also held leadership roles at Google, ALDO Group, and Sony Music, where he guided brands through digital transformation and new growth opportunities. Currently, as a senior executive at Cosmetic Physician Partners, Mr. Cohen oversees integrated marketing across a portfolio of over 55 clinics in the United States, ensuring scalable and sustainable expansion. In addition to his corporate leadership, he serves on the board of Dose Juice, advising on commercial strategy, market expansion, and operational efficiency. Mr. Cohen holds degrees in Marketing & Advertising, an MBA, and a master’s in behavioral science from the London School of Economics. Annonce • Nov 26
Cannara Biotech Inc. Plans to Launch over 20 New Products in High Volume Categories Cannara Biotech Inc. announced for fiscal 2025, the company plans to launch over 20 new products in high volume categories, including innovative formats like all-in-one vape devices under Tribal and Nugz, and premium infused pre-rolls under Tribal. A rigorous pheno-hunting program underpins these developments, unlocking unique genetics tailored to brand fit, potency, structure, and market appeal. In April 2024, Cannara introduced three new genetics: Neon Sunshine and Bubble Up (Tribal) and Guava Jam (Nugz). Annonce • Nov 12
Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025 Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025. New Risk • Sep 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€38.7m market cap, or US$43.2m). Reported Earnings • Jul 24
Third quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.033 in 3Q 2023) Third quarter 2024 results: EPS: CA$0.022 (down from CA$0.033 in 3Q 2023). Revenue: CA$19.5m (up 23% from 3Q 2023). Net income: CA$2.02m (down 31% from 3Q 2023). Profit margin: 10% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 30
Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023) Second quarter 2024 results: CA$0.038 loss per share (further deteriorated from CA$0.007 loss in 2Q 2023). Revenue: CA$19.7m (up 51% from 2Q 2023). Net loss: CA$3.45m (loss widened 458% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Jan 31
First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023) First quarter 2024 results: EPS: CA$0.023 (up from CA$0 in 1Q 2023). Revenue: CA$19.5m (up 89% from 1Q 2023). Net income: CA$2.11m (up CA$2.10m from 1Q 2023). Profit margin: 11% (up from 0% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 09
Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022) Full year 2023 results: EPS: CA$0.078 (up from CA$0.026 in FY 2022). Revenue: CA$57.6m (up 61% from FY 2022). Net income: CA$6.95m (up 201% from FY 2022). Profit margin: 12% (up from 6.4% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Dec 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Lead Director Don Olds was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Nov 13
Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024 Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024. Reported Earnings • Jul 28
Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022) Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.016 in 3Q 2022). Revenue: CA$15.9m (up 58% from 3Q 2022). Net income: CA$2.93m (up 105% from 3Q 2022). Profit margin: 18% (up from 14% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 26
Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022) Second quarter 2023 results: CA$0.007 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$13.0m (up 76% from 2Q 2022). Net loss: CA$618.1k (loss narrowed 46% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Jan 24
First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022) First quarter 2023 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2022). Revenue: CA$10.3m (up 57% from 1Q 2022). Net income: CA$3.0k (up CA$533.5k from 1Q 2022). Profit margin: 0% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Annonce • Dec 03
Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023 Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023. Recent Insider Transactions • Dec 02
Independent Director recently bought €84k worth of stock On the 30th of November, Derek Stern bought around 1m shares on-market at roughly €0.084 per share. This transaction amounted to 9.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €256k more in shares than they have sold in the last 12 months. Reported Earnings • Nov 26
Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021) Full year 2022 results: EPS: CA$0.003 (up from CA$0.002 loss in FY 2021). Revenue: CA$36.0m (up 112% from FY 2021). Net income: CA$2.31m (up CA$3.83m from FY 2021). Profit margin: 6.4% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 09
Independent Director recently bought €61k worth of stock On the 31st of August, Derek Stern bought around 720k shares on-market at roughly €0.085 per share. This transaction amounted to 7.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €172k more in shares than they have sold in the last 12 months. Reported Earnings • Jul 28
Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021) Third quarter 2022 results: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021). Revenue: CA$10.1m (up 41% from 3Q 2021). Net income: CA$1.43m (down 16% from 3Q 2021). Profit margin: 14% (down from 24% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 28
Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021) Second quarter 2022 results: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021). Revenue: CA$7.42m (up 229% from 2Q 2021). Net loss: CA$1.15m (loss widened 33% from 2Q 2021). Reported Earnings • Jan 22
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: CA$0.001 loss per share (up from CA$0.005 loss in 1Q 2021). Revenue: CA$6.56m (up 380% from 1Q 2021). Net loss: CA$530.5k (loss narrowed 85% from 1Q 2021). Revenue was in line with analyst estimates. Reported Earnings • Dec 09
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: CA$0.002 loss per share (up from CA$0.017 loss in FY 2020). Revenue: CA$17.3m (up CA$14.7m from FY 2020). Net loss: CA$1.53m (loss narrowed 88% from FY 2020). Revenue was in line with analyst estimates. Board Change • Dec 06
High number of new directors Independent Lead Director Don Olds was the last director to join the board, commencing their role in 2020. Reported Earnings • Jul 29
Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$7.16m (up CA$6.40m from 3Q 2020). Net income: CA$1.70m (up CA$4.07m from 3Q 2020). Profit margin: 24% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Annonce • Jun 12
Cannara Biotech Inc. announced that it expects to receive CAD 35 million in funding from Investissements Olymbec Inc Cannara Biotech Inc. (CNSX:LOVE) announced a non-brokered private placement of up to CAD 35,000,000 on June 10, 2021. As a part of transaction, the company will issue 107,222,222 common shares at an issue price of CAD 0.18 per share for proceeds of CAD 25,000,000 and will issue unsecured convertible debenture for proceeds of CAD 5,700,000. The transaction will include participation from Investissements Olymbec Inc. The debentures carry a coupon rate of 4% per annum, compounded semi-annually and payable along with the principal amount on the third anniversary of their issue. Subject to the approval of the TSX Venture Exchange, interest on the debentures may be payable, at the option of the company, by the issuance of common shares at CAD 0.18. The conversion price of the debenture is CAD 0.18 per common share and the number of common shares that could be issued to the investor upon conversion would be 31,666,667 common shares. Reported Earnings • Feb 01
First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020) First quarter 2021 results: Net loss: CA$3.50m (loss widened 28% from 1Q 2020). Reported Earnings • Dec 17
Full year 2020 earnings released: CA$0.017 loss per share Full year 2020 results: Net loss: CA$12.5m (loss widened 1.4% from FY 2019).